Virgin Galactic Hldgsの空売り状況は、投資家がVirgin Galactic Hldgsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Virgin Galactic Hldgs (NYSE:SPCE) 株価情報, 空売り情報

Virgin Galactic Hldgs

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

Equities

News

Markets

HOOD

SPCE

TSLA

水曜日、主要な米国の指標は全て下落し、ダウ平均株価指数は38,763.45ドルから0.6％減の、S&amp;P500は5,199.50ドルから0.8％減の、ナスダックは16,195.81ドルから1.05％減の数字をそれぞれ記録した。

ロビンフッド、テスラ株が市場を牽引　米国指数下落も影響なく

Virgin Galactic Holdings, Inc. Common Stock

Virgin Galactic Holdings Inc

Earnings

Guidance

Leggett & Platt Sees FY25 Adj. EPS $1.00-$1.20; Revenue $4.0B-$4.3B.

Earnings Misses

HTGC

Hercules Capital Q4 NII $0.49

eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) lowers FY2025 Adj EPS guidance from $0.17-$0.20 to $0.14-$0.16 vs $0.21 analyst estimate. Lowers FY2025 sales outlook from $92.00 million-$93.00 million to $88.50 million-$90.00 million vs $92.36 million estimate.

EGAN

eGain Lowers FY2025 Adj EPS Guidance from $0.17-$0.20 to $0.14-$0.16 vs $0.21 Est; Lowers FY2025 Sales Guidance from $92.00M-$93.00M to $88.50M-$90.00M vs $92.36M Est

Biotech

General

Bristol Myers Squibb Phase 3 RELATIVITY-098 Trial Of Opdualag Did Not Meet Primary endpoint

Elite Pharmaceuticals (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELTP#OTC">ELTP</a>) reported quarterly losses of $(0.01) per share. The company reported $14.36 million in sales this quarter. This is a 7.56 percent decrease over sales of $15.54 million the same period last year.

ELTP

Elite Pharmaceuticals Q3 EPS $(0.01), Sales $14.36M Down From $15.54M YoY

WIIM

DKNG

DraftKings shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and raised its FY25 revenue guidance.

Elme (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELME#NYSE">ELME</a>) is looking for FY2025 FFO of $0.91-$0.97 vs $0.94 analyst estimate..

ELME

Elme Sees FY2025 FFO $0.91-$0.97 vs $0.94 Est

Leggett &amp; Platt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 19.23 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $1.056 billion which beat the analyst consensus estimate of $1.028 billion by 2.76 percent. This is a 5.29 percent decrease over sales of $1.115 billion the same period last year.

Earnings Beats

Leggett & Platt Q4 2024 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $1.056B Beat $1.028B Estimate

DraftKings Raises FY25 Revenue From $6.2B-$6.6B To $6.3B-$6.6B Vs $6.394B Est.

Elme Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELME#NYSE">ELME</a>) reported quarterly earnings of $0.24 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $61.26 million which beat the analyst consensus estimate of $60.49 million by 1.27 percent. This is a 4.10 percent increase over sales of $58.85 million the same period last year.

Elme Communities Q4 FFO $0.24, Inline, Sales $61.26M Beat $60.49M Estimate

The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.

Bio-Rad Offers To Buy  All Equity Interests In Digital PCR Developer Stilla Technologies; No Terms Disclosed

cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) reported quarterly losses of $(0.22) per share. This is a 67.16 percent increase over losses of $(0.67) per share from the same period last year. The company reported $5.11 million in sales this quarter. This is a 4.87 percent decrease over sales of $5.38 million the same period last year.

YCBD

cbdMD Q1 EPS $(0.22) Up From $(0.67) YoY, Sales $5.11M Down From $5.38M YoY

DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.15) by 193.33 percent. This is a 51.72 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $1.393 billion which missed the analyst consensus estimate of $1.433 billion by 2.82 percent. This is a 13.16 percent increase over sales of $1.231 billion the same period last year.

DraftKings Q4 2024 Adj. EPS $0.14 Beats $(0.15) Estimate, Sales $1.393B Miss $1.433B Estimate

InflaRx N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company's ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are to be sold by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
The Company expects to grant the underwriters a 30-day option to purchase additional ordinary shares at the public offering price, less the underwriting discount.
The Company intends to use the net proceeds from the offering primarily to fund clinical development of its pipeline candidates, including vilobelimab and INF904, and for general corporate purposes.&nbsp;

Offerings

IFRX

InflaRx Announces Public Offering Of Ordinary Shares And Pre-Funded Warrants; No Size Or Amount Disclosed

Management

VRSN

Verisign Announces Retirement Of CFO George E. Kilguss III, Effective May 31, 2025. John D. Calys, Has Been Appointed To Succeed Mr. Kilguss , Effective Upon Mr. Kilguss' Retirement

eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) Q3 expected to be below $0.02 vs $0.07 Est. sees Q3 sales of $21.000 million-$21.500 million vs $23.56 million analyst estimate.

eGain Q3  expected to be below $0.02 vs $0.07 Est; Sees Q3 Sales $21.000M-$21.500M vs $23.56M Est

Commercial Vehicle Group (the "Company" or "CVG") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>), a diversified industrial products and services company, is pleased to announce the appointment of Scott Reed as Chief Operating Officer, effective February 13, 2025. Mr. Reed comes to CVG with more than 30 years of diverse business and leadership experience in industrial and manufacturing organizations.
In his new role, Mr. Reed will oversee the global manufacturing and supply chain operations of the company, driving operational excellence and strengthening cross-functional alignment across planning and execution, ensuring that our operational processes are aligned with our strategic goals. He will report to James Ray, President and CEO of CVG, and serve on the executive leadership team.

CVGI

CVG Appoints Scott Reed As Chief Operating Officer, Effective February 13, 2025

AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) affirms FY2025 sales outlook from $100.00 million-$106.00 million to $100.00 million-$106.00 million vs $103.83 million estimate.

RCEL

AVITA Medical Affirms FY2025 Sales Guidance of $100.00M-$106.00M vs $103.83M Est

President Donald Trump promised tariffs on China during the 2024 election and the country remains one of his key targets in increasing payments on items imported into <a href="https://www.benzinga.com/news/global/25/02/43442219/why-beer-tequila-avocados-cars-iphone-prices-could-rise-trumps-tariffs-on-canada-mexico-china-to-hurt-several-sectors">the United States.</a>
Here's a look at how Benzinga readers feel that could impact the American economy.
What Happened: Trump <a href="https://www.benzinga.com/news/global/25/01/42988641/trump-wants-trade-partners-to-start-paying-announces-external-revenue-service-for-tariffs">has imposed tariffs</a> on several items exported to the United States by China and new comments suggest more tariffs could be coming.
On Thursday, Trump said the White House will go country by country and adjust trade relations with "fair and reciprocal" tariffs.
"I've decided, for purposes of fairness, that I will charge a reciprocal tariff, meaning whatever countries charge the United States of America," Trump said, as <a href="https://www.nbcnews.com/business/economy/trump-reciprocal-tariffs-what-products-countries-how-much-rcna192075">reported </a>by NBC. "In almost all cases, they're charging us vastly more than we charge them but those days are over."
Benzinga recently polled readers to see if they think the tariffs on China will be good or bad for the American economy.
"Will Trump's tariffs on China help or hurt the U.S. economy?" Benzinga asked.
The results were:
<ul>
<li>Hurt businesses and consumers: 54%</li>
<li>Help the economy: 36%</li>
<li>No real impact: 10%</li>
</ul>
The winner of the poll was that tariffs on China will hurt businesses and consumers in America.
Read Also:<a href="https://www.benzinga.com/markets/25/02/43686104/mitch-mcconnell-criticizes-trumps-tariff-plans-warns-of-potential-price-hike-big-lingering-concerns-for-american-industry-and-workers"> Mitch McConnell Criticizes Trump&#8217;s Tariff Plans, Warns Of Potential Price Hike: &#8216;Big, Lingering Concerns For American Industry And Workers&#8217;</a>
Why It's Important: News of Trump considering reciprocal tariffs follows earlier tariff threats primarily aimed at Canada, China, and Mexico.
China is now<a href="https://www.benzinga.com/news/global/25/02/43600852/china-sets-sights-on-us-tech-companies-as-trade-tensions-rise"> turning its attention </a>to targeting American technology companies with trade relations escalating according to a new report.
The Wall Street Journal said China is looking at targeting American tech companies with antitrust concerns in the country. The list of companies China could target includes Nvidia, Apple, Broadcom and Alphabet. &nbsp;
Concerns over the American economy with tariff threats could change the way investors view the potential returns of the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 Index, for 2025.
A previous <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43041374/exclusive-how-high-will-sp-500-go-under-donald-trump-in-2025-readers-are-optimistic-26-say-this">Benzinga reader survey</a> asked how high investors thought the SPY could go in 2025, Trump's first year back in the White House.
In 2017, the SPDR S&amp;P 500 ETF Trust was up 21.7%. This was the first year with Trump in office and many sectors saw gains during the year.
When asked what they thought the return of the SPY would be in 2025, these were the results:
<ul>
<li>16%+: 26%</li>
<li>11% to 15%: 22%</li>
<li>Will Decline: 22%</li>
<li>6% to 10%: 19%</li>
<li>0% to 5%: 12%</li>
</ul>
The poll found that the largest percentage believed that the S&amp;P 500 Index would post gains of at least 16% in 2025. The 11% to 15% range came in second place at 22%.
It&#8217;s also worth pointing out that the S&amp;P 500 decline in 2025 was tied for second in the poll at 22%, which could mean 2025 is a make-or-break year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43216599/elon-musk-tucker-carlson-ron-desantis-joe-rogan-or-marjorie-taylor-greene-poll-finds-this-figure-most-likely-to-buy-trump-coin">Elon Musk, Tucker Carlson, Ron DeSantis, Joe Rogan Or Marjorie Taylor Greene: Who&#8217;s Most Likely To Buy Trump Coin?</a></li>
</ul>
The study was conducted by Benzinga from Feb. 11, 2025 through Feb. 12, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 133 adults.
Image created using photos from Shutterstock.

Politics

Global

Exclusives

EXCLUSIVE: Will Trump's Chinese Tariffs Help Or Hurt America's Economy? 54% Say This…

"Through February 11, we have generated approximately $750 million of transaction revenue, and we expect Q1 subscription and services revenue to be within a range of $685-$765 million. We expect Q1 transaction expenses will be in the mid-to-high teens as a percentage of net revenue. We expect technology &amp; development and general &amp; administrative expenses to range from $750-$800 million reflecting growth in variable expenses related to elevated Trading Volume as well as payroll taxes and headcount. Finally, we expect sales and marketing expenses to increase Q/Q to $235-$375 million, driven by potential variability in i) performance marketing, and ii) USDC assets in our product suite which drive USDC rewards."

COIN

Coinbase Expects Q1 Subscription And Services Revenue To Be $685M - $765M

Bullish option flow detected in Virgin Galactic (SPCE) with 14,239 calls trading, 3x expected, and implied vol increasing almost 3 points to 94.85%...

Virgin Galactic call volume above normal and directionally bullish

Bullish option flow detected in Virgin Galactic (SPCE) with 15,028 calls trading, 2x expected, and implied vol increasing almost 10 points to 89.98...

Bullish option flow detected in Virgin Galactic (SPCE) with 9,747 calls trading, 2x expected, and implied vol increasing almost 4 points to 96.59%....

Virgin Galactic snaps seven straight days of losses

Bullish option flow detected in Virgin Galactic (SPCE) with 24,209 calls trading, 9x expected, and implied vol increasing almost 16 points to 95.23...

Virgin Galactic: Downward Spiral

Bullish option flow detected in Virgin Galactic (SPCE) with 12,616 calls trading, 3x expected, and implied vol increasing over 7 points to 100.09%....

Undercovered Dozen: Virgin Galactic, Gold Fields, Matador Resources, EHang +

There are songs that no one should sing at karaoke, just as there are stocks that no one should buy. What are some terrible karaoke songs that align with the stocks you must avoid? I'll give you three.

Comments

Virgin Galactic Hldgs

空売り

Virgin Galactic Hldgs (NYSE:SPCE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル